Browsing: Approval

The US Food and Drug Administration (FDA) has approved ViiV Healthcare’s Tivicay PD (dolutegravir), for use with other antiretroviral agents in paediatric patients with human immunodeficiency virus type 1 (HIV-1) who weigh at least 2kg

Rare disease specialist Ultragenyx’s gene therapy Genglycos has received accelerated approval from the FDA for treatment of glycogen storage disease type Ia (GSDIa), a rare metabolic condition

This kind of move into rare disease therapies is part of a broader push across healthcare to develop more precise, technology driven treatments. You can explore other companies linked to this theme through 42 healthcare AI stocks

Regeneron has won FDA approval for garetosmab in fibrodysplasia ossificans progressiva, giving the biotech a commercial product built on its scientific breakthrough in the ultrarare disease. It also sets up a showdown with Ipsen, which owns the only other FOP drug on the market

The approval of an oral version of Wegovy in the EU could broaden the impact of GLP-1 medicines on the food and beverage industry, as easier access to weight-management treatment potentially brings more consumers into a market already showing changes in appetite, purchasing behavior, and nutritional priorities

GLP-1 weight loss tablet approval: why it matters for brokers | Insurance Business

MedPal AI (MPAL ), the AI-native digital health and pharmacy group, has highlighted that the UK has become the first country in Europe to authorise orforglipron (brand name Foundayo), Eli Lilly’s once daily oral GLP-1 tablet

In a significant development for weight management and diabetes treatment, Britain’s medicines regulator has authorized Eli Lilly’s new pill, Foundayo. This move makes the UK the first European country to approve the tablet for both conditions

Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>

WESTLAKE VILLAGE, Calif., and BOSTON, July 24, 2026 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Furoscix ReadyFlow™ (furosemide injection) for the treatment of edema…